АРТЕРИАЛЬНАЯ ГИПЕРТОНИЯ НА ФОНЕ ТЕРАПИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ ИНГИБИТОРАМИ АНГИОГЕНЕЗА: СЕРЬЕЗНОЕ ПРЕПЯТСТВИЕ ИЛИ УПРАВЛЯЕМАЯ РЕАКЦИЯ?

Обложка

Цитировать

Полный текст

Об авторах

Ж. Д. Кобалава

ФГАОУ ВО «Российский университет дружбы народов» Минобрнауки России

Email: fake@neicon.ru

117198 Москва, ул. Миклухо-Маклая, 6

Россия

Е. К. Шаварова

ФГАОУ ВО «Российский университет дружбы народов» Минобрнауки России

Автор, ответственный за переписку.
Email: alisheva@rambler.ru

Елена Курбановна Шаварова.

117198 Москва, ул. Миклухо-Маклая, 6

Россия

Список литературы

  1. Yeh E.Т.Н., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53(24):2231–47. doi: 10.1016/j.jacc.2009.02.050. PMID: 19520246.
  2. Zamorano J.L., Lancellotti P., Rodriguez-Muñoz D. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768–2801. doi: 10.1093/eurheartj/ehw211. PMID: 27567406.
  3. Maitland L.M., Bakris G.L., Black H.R. et al. Initial assessment, surveillance and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102(9):596–604. doi: 10.1093/jnci/djq091.
  4. Schlumberger M., Tahara M., Lori J. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med 2015;372(7):621–30. doi: 10.1056/NEJMoa1406470.
  5. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008;358(19): 2039–49. doi: 10.1056/NEJMra0706596.
  6. Nazer B., Humphreys BD., Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardio-vascular system: focus on hypertension. Circulation 2011;124(15):1687–91. doi: 10.1161/CIRCULATIONAHA.110.992230.
  7. Hayman S.R., Leung N., Grande J.P., Garovic V.D. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012;14(4):285–94. doi: 10.1007/s11912-012-0242-z.
  8. Zerbini G., Lorenzi M., Palini A. Tumor angiogenesis. N Engl J Med 2008;359(7):763; author reply 764. doi: 10.1056/NEJMc081278.
  9. Holmes K., Roberts O.L., Thomas A.M., Cross M.J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 2007:19(10);2003–12. doi: 10.1016/j.cellsig.2007.05.013. PMID: 17658244.
  10. Mourad J.J., des Guetz G., Debbabi H., Levy B.I. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19:927–34. doi: 10.1093/annonc/mdm550. PMID: 18056916.
  11. Steeghs N., Gelderblom H., Roodt J.O. et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008;14(11):3470–6. doi: 10.1158/1078-0432.CCR-07-5050.
  12. Veronese M.L., Mosenkis A., Flaherty K.T. et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24(9):1363–9. doi: 10.1200/JCO.2005.02.0503. PMID: 16446323.
  13. Kappers M.H., van Esch J.H., Sluiter W. et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56(4):675–81. doi: 10.1161/HYPERTENSIONAHA.109. 149690.
  14. Mir O., Ropert S., Alexandre J., Goldwasser F. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 2009;20(5):967–70. doi: 10.1093/annonc/mdp206.
  15. Azizi M., Chedid A., Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358(1):95–7. doi: 10.1056/NEJMc072330.
  16. Piccirillo J.F., Tierney R.M., Costas I. et al. Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry. JAMA 2004;291(20):2441–7. doi: 10.1001/jama.291.20.2441. PMID: 15161894.
  17. Chu T.F., Rupnick M.A., Kerkela R. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370(9604):2011–9. doi: 10.1016/S0140-6736(07)61865-0.
  18. Maitland M.L., Kasza K.E., Karrison T.G. et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. ClinCancerRes. 2009;15(19):6250–7. doi: 10.1158/1078-0432.CCR-09-0058.
  19. Maitland M.L., Bakris G.L., Black H.R. et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102(9):596–604. doi: 10.1093/jnci/djq091.
  20. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии. Российские рекомендации, четвертый пересмотр. Системные гипертензии 2010;(3):5–26. [Chazova I.E., Ratova L.G., Boytsov S.A., Nebieridze D.V. Diagnosis and treatment of hypertension. Russian recommendations, fourth revision. Sistemnye gipertenzii = Systemic Hypertension 2010;(3):5–26. (In Russ.)].
  21. Mancia G., De Backer G., Dominiczak A. et al. 2013 The task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J 2013;34(28):2159–219. doi: 10.1093/eurheartj/eht151.
  22. Nazer B., Humphreys BD., Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011;124(15):1687–91. doi: 10.1161/CIRCULATIONAHA.110.992230.
  23. Zhu X., Wu S., Dahut W.L. et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186–93. doi: 10.1053/j.ajkd.2006.11.039. PMID: 17261421.
  24. Powe D.G., Voss M.J., Zanker K.S. et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1(7):628–38. doi: 10.18632/oncotarget.101009.
  25. Barron T.I., Connolly R.M., Sharp L. et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011;29(19):2635–44. doi: 10.1200/JCO.2010.33.5422.
  26. Melhem-Bertrandt A., Chavez-Macgregor M., Lei X. et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011;29(19): 2645–52. doi: 10.1200/JCO.2010.33.4441.
  27. Zhang D., Ma Q.Y., Hu H.T. et al. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting creb, nfkappab and ap-1. Cancer BiolTher 2010;10:19–29. PMID: 20424515.
  28. Liao X., Che X., Zhao W. et al. The beta-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappa-b signaling. Oncol Rep 2010;24(6):1669–76. PMID: 21042766.
  29. Park P.G., Merryman J., Orloff M. et al. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 1995;55(16):3504–8. PMID: 7627955.
  30. Yang E.V., Sood A.K., Chen M. et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngealcarcinoma tumor cells. Cancer Res 2006;66:10357–64. doi: 10.1158/0008-5472.CAN-06-2496. PMID: 17079456.
  31. Sood A.K., Bhatty R., Kamat A.A. et al. Stresshormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369–75. doi: 10.1158/1078-0432.CCR-05-1698.
  32. Pasquier E., Ciccolini J., Carre M. et al. Propranolol potentiates the antiangiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011;2(10):797–809. doi: 10.18632/oncotarget.343.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.